WO1994013263A1 - Stabilized medicinal aerosol solution formulations - Google Patents

Stabilized medicinal aerosol solution formulations Download PDF

Info

Publication number
WO1994013263A1
WO1994013263A1 PCT/US1993/011856 US9311856W WO9413263A1 WO 1994013263 A1 WO1994013263 A1 WO 1994013263A1 US 9311856 W US9311856 W US 9311856W WO 9413263 A1 WO9413263 A1 WO 9413263A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
aerosol solution
solution formulation
formulation according
cosolvent
Prior art date
Application number
PCT/US1993/011856
Other languages
French (fr)
Inventor
Paul D. Jager
Mark J. Kontny
Jurgen H. Nagel
Original Assignee
Jager Paul D
Kontny Mark J
Nagel Jurgen H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26850651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1994013263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jager Paul D, Kontny Mark J, Nagel Jurgen H filed Critical Jager Paul D
Priority to AU60486/94A priority Critical patent/AU6048694A/en
Publication of WO1994013263A1 publication Critical patent/WO1994013263A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Definitions

  • This invention relates to stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to stable pharmaceutical solution formulations suitable for aerosol administration wherein either a strong inorganic acid or a weak organic acid is added to the aerosol solution formulation which contains a medicament in solution with an environmentally safe hydrofluorocarbon (HFC) as a propellant, together with an organic compound as a cosolvent.
  • HFC hydrofluorocarbon
  • the acid provides stability against degradation or decomposition of the medicament resulting largely from interaction of the medicament with the cosolvent and/or water present in the solution formulation.
  • aerosol formulations of medicaments by means of pressurized, metered-dose inhalers (MDIs) is used widely in therapy, such as in the treatment of obstructive airway diseases and asthma.
  • MDIs pressurized, metered-dose inhalers
  • inhalation provides more rapid onset of action while minimizing systemic side effects.
  • Aerosol formulations can be administered by inhalation through the mouth or topically by application to the nasal mucosa.
  • Formulations for aerosol administration via MDIs can be solutions or suspensions.
  • Solution formulations offer the advantage of being homogeneous in nature with the medicament and excipients completely dissolved in the propellant vehicle. Solution formulations also obviate physical stability problems associated with suspension formulations and thus assure more consistent uniform dosage administration while also eliminating the need for surfactants.
  • the propellant comprised a mixture of chlorofluorocarbons (CFCs) to provide the desired solubility, vapor pressure, and stability of the formulation.
  • CFCs chlorofluorocarbons
  • HFC hydrofluorocarbon
  • 4,174,295 discloses the use of propellant systems consisting of combinations of HFCs, which may also contain a saturated hydrocarbon component, suitable for application in the fields of home products such as hair lacquers, anti- perspiration products, perfumes, deodorants, paints, insecticides and the like.
  • HFC-134(a) 1,1,1,2-tetrafluoroethane
  • Adjuvant a compound having a higher polarity than the HFC-134(a)
  • surface active agent a compound having a higher polarity than the HFC-134(a)
  • W091/11496 discloses the use of 1,1,1,2,3,3,3- heptafluoropropane (HFC-227) , optionally mixed with other propellant components, for use in preparing suspension aerosol formulations of medicaments.
  • aerosol suspension formulation means a pharmaceutical formulation of a medicament suitable for aerosol administration wherein the medicament and excipients are present in the form of a finely divided suspension.
  • aerosol solution formulation means a pharmaceutical formulation of a medicament suitable for aerosol administration wherein the medicament and excipients are completely dissolved.
  • stable aerosol solution formulation means an aerosol solution formulation which exhibits substantial chemical stability over time.
  • Ipratropium bromide is an anticholinergic bronchodilator marketed under the trademark "ATROVENT.”
  • This medicament is administered as an aerosol suspension formulation which contains a mixture of CFCs (dichlorodifluoromethane, dichlorotetrafluoroethane, and trichloromonofluoromethane) as the propellant, and soya lecithin.
  • ipratropium bromide stable aerosol solution formulations of ipratropium bromide can be obtained by dissolving ipratropium bromide in a homogeneous system comprising HFC-134(a), ethanol, and a strong inorganic acid or a weak organic acid.
  • the particular type and amount of acid added to the system will define the level of acidity which is critical in obtaining a stable solution formulation.
  • the present invention provides stabilized aerosol solution formulations comprising a medicament, an HFC propellant, a cosolvent, and a strong inorganic acid or weak organic acid.
  • a small amount of water may also be present in the propellant/cosolvent system.
  • Suitable HFC propellants are those which, when mixed with the cosolvent(s) , form a homogeneous propellant system in which a therapeutically effective amount of the medicament can be dissolved.
  • the HFC propellant must be toxicologically safe and must have a vapor pressure which is suitable to enable the medicament to be administered via a pressurized MDI. Additionally, the HFC propellant must be compatible with the components of the MDI device (such as containers, valves, and sealing gaskets, etc.) which is employed to administer the medicament.
  • Preferred HFC propellants are 1,1,1,2-tetrafluoroethane (HFC-134(a)) and 1,1,1,2,3,3,3,-heptafluoropropane (HFC-227) .
  • HFC-134(a) is particularly preferred.
  • Other examples of HFC propellants are HFC-32 (difluoromethane) , HFC-143(a) (1,1,1- trifluoroethane) , HFC-134 (1,1,2,2-tetrafluoroethane) , and HFC-152a (1,1-difluoroethane) .
  • non-halogenated hydrocarbon propellants may be used in place of the HFC propellants in the present invention.
  • non-halogenated hydrocarbons are saturated hydrocarbons, including propane, n-butane, and isobutane, and ethers, including diethyl ether.
  • a substantially non-aqueous HFC propellant/cosolvent system is preferred.
  • Water may be present in small amounts as an impurity in the HFC propellant/cosolvent system, or, if desired, small amounts of water may be added (up to about 5% by weight) to the HFC/propellant system, for example, to aid in manufacturing.
  • pharmaceutically acceptable excipients can be included in the aerosol solution formulations of the present invention.
  • a soluble surface active agent can be added in order to improve the performance of valve systems employed in the MDI devices used for the aerosol administration of the formulations.
  • preferred surface active agents are oleic acid, sorbitan trioleate, lecithin, and isopropylmyristate.
  • antioxidants for example ascorbic acid and tocopherol
  • taste masking agents for example, menthol, sweeteners, and artificial or natural flavors
  • pressure modifying agents for example, n-pentane, iso-pentane, neo-pentane, and n-hexane.
  • the medicaments used in the present invention may be any substance which is suitable for aerosol administration from an MDI or similar device.
  • the medicament must be soluble in the HFC propellant/cosolvent system and, characteristically exhibit significant degradation or decomposition in the HFC propellant/cosolvent system.
  • the degradation or decomposition of the medicament must be acid sensitive in that the rate of degradation or decomposition can be effectively reduced by the addition of acid.
  • the decomposition and the degradation of the medicament may occur by various chemical mechanisms, the most significant being interaction of the medicament with the cosolvent or with the water present in the system to form hydrolysis, esterification, and/or ether products.
  • the amount of medicament employed in the aerosol solution formulations of the present invention is that which is effective in producing the intended therapeutic effect, i.e., an amount such that one or more etered volumes of the formulation will deliver an effective amount of the medicament. It will be apparent to those skilled in the art that the potency of the particular medicament employed in the aerosol solution formulation will determine the amount of medicament in the formulation. In general, the medicament is present in an amount from about 0.001 to 10 percent by weight of the total weight of the formulation. An amount of from about 0.01 to 1.0 percent by weight of the total weight of the formulation is preferred.
  • Bronchodilators are the preferred class of medicaments for use in the aerosol solution formulations of the present invention.
  • classes of medicaments can in general be used. Examples of such classes are: antihistamines, antiallergics, antiinflammatories, PAF-antagonists, antitussives, antibiotics, mast cell stabilizers, mucolytics, antineoplastics, antiinfectives, vaccines, anesthetics, diagnostic agents, analgesics, antianginals, leukotriene antagonists, and 5-lipoxygenase antagonists.
  • the medicaments can also be various types of organic molecules, including, but not limited to, hormones, enzymes, proteins, peptides, steroids, alkaloids, or combinations thereof.
  • the most preferred example of the medicaments for use in the aerosol solution formulations of the present invention is ipratropium bromide.
  • Other preferred examples are oxitropium bromide (BA253) , albuterol, metapraterenol, tiotropium bromide (BA-679) , and fenoterol.
  • alpha-adrenergic agonists ephedrine, epinephrine. norfenefrine, phenylephrine, and phenylpropanolamine.
  • beta-adrenergic agonists bambuterol, bitoterol, carbuterol, clenbuterol, ephedrine, formoterol, hexoprenaline, isoproterenol, mabuterol, pirbuterol, reproterol, rimiterol, terbutaline, and tulobuterol.
  • Anticholiner ⁇ ic Bronchodilators telenzepine, troventol, and flubron.
  • Alkaloids atropine, scopolamine, and bromocriptine.
  • the medicaments used in the present invention may be in the form of either the free base or a pharmaceutically acceptable, non-toxic, salt thereof.
  • Suitable salts are well known in the pharmaceutical and medicinal arts. The selection of a particular salt will depend upon the chemical nature of the base and the chemical stability and solubility of the salt in the formulation.
  • salts examples include: acetate, benezenesulphonate, benzoate, bicarbonate, bitartrate, bromide, calcium edentate, camsylate, esylate, fumarate, fluceptate, gluconate, glutamate, glycolarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methysulfate, mucate, napsylate, nitrate, pamoate (embonate) , pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulphate, tannate, tartrate, and triethiodide.
  • Cationic salts may also be used.
  • cationic salts include the alkali metals, e.g. sodium and potassium, and ammonium salts and salts of amines known to be pharmaceutically acceptable, e.g., glycine, ethylene diamine, choline, diethanolamine, triethanolamine, octadecylamine, diethylamine, triethylamine, l-amino-2-propanol-amino-2-(hydroxymethyl) propane-1,3-diol and 1-3(3, 4-dihydroxyphenyl)-2- isopropylaminoethanol.
  • alkali metals e.g. sodium and potassium
  • ammonium salts and salts of amines known to be pharmaceutically acceptable e.g., glycine, ethylene diamine, choline, diethanolamine, triethanolamine, octadecylamine, diethylamine, triethylamine, l-amino
  • cosolvent may be any one of a number of organic solvents that are toxicologically safe and amenable to MDI solution formulations.
  • solvent is meant any solvent which is miscible in the formulation in the amount desired and which, when added provides a formulation in which the medicament can be dissolved in therapeutically effective amounts.
  • alcohols for example, ethyl alcohol and isopropyl alcohol
  • glycols for example, propylene glycol, polyethylene glycols, polypropylene glycols, glycol ethers, and block copolymers of oxyethylene and oxypropylene
  • other substances for example, glycerol, polyoxyethylene alcohols, and polyoxtethylene fatty acid esters.
  • cosolvents that may be inert to interaction with the medicament(s) are hydrocarbons, for example, n-propane, n-butane, isobutane, n-pentane, iso- pentane, neo-pentane, and n-bexane; and ethers, for example, diethyl ether.
  • hydrocarbons for example, n-propane, n-butane, isobutane, n-pentane, iso- pentane, neo-pentane, and n-bexane
  • ethers for example, diethyl ether.
  • a preferred cosolvent according to this invention is ethyl alcohol (ethanol) .
  • the purpose of the cosolvent is to increase the solubility of the medicament and the excipients in the formulation.
  • the amount of cosolvent present in the formulation defines the maximum amount of medicament and excipients that can be dissolved at a particular temperature.
  • the selection of the acid in the aerosol solution formulations of this invention depends on the medicament used and the acid concentration needed to effect an acceptable rate of degradation of the medicament.
  • the acid may be any strong inorganic or mineral acid, for example, hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid, or the like.
  • the acid may also be selected from the group of acids known to those skilled in the art as organic acids, which are considered to be weak acids relative to the strong inorganic acids. Representative of this group and preferred in this invention are ascorbic acid and citric , , , acid, although other organic acids may also be suitable.
  • an aerosol solution formulation comprising a particular medicament may be formulated using acids selected from either of the above groups.
  • the methods used to introduce the acid into the formulation may include: (1) the direct addition of a strong inorganic acid or weak organic acid; (2) the addition of the medicament as an acidic salt thereby generating the correct acidity level in situ, and (3) combinations of (1) and (2) .
  • Appropriate salts for introducing the medicament into the formulation will be apparent to those skilled in the art.
  • the decomposition can be attributed to oxidation, chemical dehydration, hydrolysis and esterification.
  • tropic acid ethyl ester is the chief degradation product.
  • This ester can be formed by the direct reaction of ethanol with ipratropium bromide or by hydrolysis of ipratropium bromide followed by esterification of tropic acid with ethanol. Addition of 1% water reduced the decomposition due to dehydration. Carrying out the reaction under nitrogen atmosphere reduced the oxidation products.
  • a range of chemical compositions is given in Table 1 for aerosol solution formulations containing ipratropium bromide, HFC-134(a), and a strong inorganic acid, such as - hydrochloric, nitric phosphoric, or sulfuric acid.
  • the amount of alcohol present in the formulation defines the maximum amount of ipratropium bromide that can be dissolved at a particular temperature.
  • the range of ipratropium bromide concentrations given in Table 1 is based on the 0 maximum, amount that can be safely dissolved without precipitation at room temperature for a given alcohol concentration.
  • Acid content is given in units of normality which defines a pH range equivalent to 2.0 - 4.7 in an aqueous system.
  • Ipratropium Bromide as the Monohydrate 0.001 - 2.5% wght./wght.
  • solubility limitations must also be taken into consideration given the fact that ascorbic acid is only soluble to about 20 mg/ml in absolute ethanol and is expected to have a lesser solubility in an absolute ethanol/HFC-134a system. Optimally, about 0.30 mg/ml of ascorbic acid is expected to be required in such a formulation corresponding to a pH-degradation rate minimum of pH 3.5 for ipratropium bromide in an aqueous system.
  • Table 2 The information contained in Table 2 is presented for ascorbic acid and gives a range of ethanol content that is based on the expected room temperature solubility of ipratropium bromide (as the monohydrate) , not taking into account the solubility limit of ascorbic acid in such a HFC-134a system. Optimally, about 0.30 mg/ml of ascorbic acid is expected to be required in such a formulation corresponding to a pH- degradation rate minimum of pH 3.5 for ipratropium bromide in an aqueous system.
  • the range of acid concentration required to effect an acceptable rate of decomposition for medicaments in primarily non-aqueous solution aerosol formulations will depend primarily on the chemical composition of the formulation (such as choice of cosolvent(s) and the chemical nature of the medicaments(s) present. This range is expected to be about 0.10 - 0.0000001 normal for strong inorganic acids corresponding to an aqueous pH range of about 1.0-7.0 and must be calculated for weak organic acids depending on their pKa values.
  • Ipratropium Bromide as the Monohydrate 0.001 - 2.5 % wght. wght.
  • the amount of drug that can be delivered through the valve of an aerosol solution formulation will depend on the active ingredient concentration (mg/ml ) in the formulation and the metering volume (ul ) of the valve . Commonly used valve sizes are 25 , 50 , 63 and 100 ul .
  • Metered dose inhalers containing aerosol solution formulations of medicaments can be manufactured using a number of conventional processing methods .
  • One method, which is useful in the laboratory for the manufacture of small laboratory scale lots is Dual Stage Pressure Fill . This method is shown in Tables 3 and 4 for two specific ipratropium bromide solution formulations using a 50 -ul valve .
  • Two methods for large scale manufacture are Single- stage Cold Fill and Single- Stage Pressure Fill .
  • An active ingredient concentrate is prepared by dissolving the ipratropium bromide , as the monohydrate , nitric acid, and water in ethyl alcohol .
  • the concentrate is added to an appropriate filling apparatus .
  • the active ingredient concentrate is dispensed into aerosol containers .
  • the headspace of the containers is purged with nitrogen or HFC- 134a vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valves .
  • the HFC- 134a propellant is then pressure- filled into the sealed containers .
  • An active ingredient concentrate is prepared by dissolving the ipratropium bromide, as the monohydrate, ascorbic acid and water in ethyl alcohol. The concentrate is added to an appropriate filling apparatus. The active ingredient concentrate is dispensed into aerosol containers, the headspace of the containers is purged with Nitrogen or HFC-134a vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valves. The HFC-134a propellant is then pressure filed into the sealed containers.

Abstract

Stabilized medicinal aerosol solution formulations comprising medicaments that tend to degrade by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either a strong inorganic acid or weak organic acid are described.

Description

STABILIZED MEDICINAL AEROSOL SOLUTION FORMULATIONS
This invention relates to stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to stable pharmaceutical solution formulations suitable for aerosol administration wherein either a strong inorganic acid or a weak organic acid is added to the aerosol solution formulation which contains a medicament in solution with an environmentally safe hydrofluorocarbon (HFC) as a propellant, together with an organic compound as a cosolvent. The acid provides stability against degradation or decomposition of the medicament resulting largely from interaction of the medicament with the cosolvent and/or water present in the solution formulation. ,
BACKGROUND OF THE INVENTION
The administration of aerosol formulations of medicaments by means of pressurized, metered-dose inhalers (MDIs) is used widely in therapy, such as in the treatment of obstructive airway diseases and asthma. Compared with oral administration, inhalation provides more rapid onset of action while minimizing systemic side effects. Aerosol formulations can be administered by inhalation through the mouth or topically by application to the nasal mucosa.
Formulations for aerosol administration via MDIs can be solutions or suspensions. Solution formulations offer the advantage of being homogeneous in nature with the medicament and excipients completely dissolved in the propellant vehicle. Solution formulations also obviate physical stability problems associated with suspension formulations and thus assure more consistent uniform dosage administration while also eliminating the need for surfactants.
The administration of aerosol solution formulations via MDIs is dependent upon the propulsive force of the propellant system used in its manufacture.
ULE 25 Traditionally, the propellant comprised a mixture of chlorofluorocarbons (CFCs) to provide the desired solubility, vapor pressure, and stability of the formulation. However, since it has been established in recent years that CFCs are environmentally harmful because they contribute to the depletion of the Earth's ozone layer, it is desirable to substitute environmentally safe hydrofluorocarbon (HFC) propellants or other non-chlorinated propellants for environmentally harmful CFC propellants in aerosol inhalation formulations. For example, U.S. Patent No. 4,174,295 discloses the use of propellant systems consisting of combinations of HFCs, which may also contain a saturated hydrocarbon component, suitable for application in the fields of home products such as hair lacquers, anti- perspiration products, perfumes, deodorants, paints, insecticides and the like.
It is known in the art that certain HFCs have properties suitable for use as propellants for the aerosol administration of medicaments. For example, published European Patent Application No. 0 372 777 (EPO89312270.5) describes the use of 1,1,1,2-tetrafluoroethane (HFC-134(a)) in combination with at least one "adjuvant" (a compound having a higher polarity than the HFC-134(a)) and a surface active agent to prepare suspension and solution formulations of medicaments suitable for administration by the aerosol route. Also, PCT Published Application No. W091/11496 (PCT/EP91/00178) discloses the use of 1,1,1,2,3,3,3- heptafluoropropane (HFC-227) , optionally mixed with other propellant components, for use in preparing suspension aerosol formulations of medicaments. BRIEF DESCRIPTION OF THE INVENTION
It has now been found that the use of propellant systems containing an HFC and a cosolvent in aerosol solution formulations presents a chemical stability problem that has not been previously recognized or resolved in the prior art. This is because in such HFC propellant/cosolvent systems, the medicament may interact with the cosolvent and/or water present in the system to produce decomposition or degradation products. It has now further been found that the addition of an acid, either a strong inorganic acid or a weak organic acid, to the HFC propellant/cosolvent system provides the requisite chemical stability to the medicament.
BRIEF DESCRIPTION OF THE DRAWING Figure 1 is a graph that summarizes invention results.
DESCRIPTION OF THE PREFERRED EMOBDIMENTS The term "aerosol suspension formulation" means a pharmaceutical formulation of a medicament suitable for aerosol administration wherein the medicament and excipients are present in the form of a finely divided suspension.
The term "aerosol solution formulation" means a pharmaceutical formulation of a medicament suitable for aerosol administration wherein the medicament and excipients are completely dissolved.
The term "stabilized aerosol solution formulation" means an aerosol solution formulation which exhibits substantial chemical stability over time.
Ipratropium bromide is an anticholinergic bronchodilator marketed under the trademark "ATROVENT." This medicament is administered as an aerosol suspension formulation which contains a mixture of CFCs (dichlorodifluoromethane, dichlorotetrafluoroethane, and trichloromonofluoromethane) as the propellant, and soya lecithin.
Studies have demonstrated that stable aerosol solution formulations of ipratropium bromide can be obtained by dissolving ipratropium bromide in a homogeneous system comprising HFC-134(a), ethanol, and a strong inorganic acid or a weak organic acid. The particular type and amount of acid added to the system will define the level of acidity which is critical in obtaining a stable solution formulation. Thus, the present invention provides stabilized aerosol solution formulations comprising a medicament, an HFC propellant, a cosolvent, and a strong inorganic acid or weak organic acid. A small amount of water (up to about 5% by weight) may also be present in the propellant/cosolvent system.
Suitable HFC propellants are those which, when mixed with the cosolvent(s) , form a homogeneous propellant system in which a therapeutically effective amount of the medicament can be dissolved. The HFC propellant must be toxicologically safe and must have a vapor pressure which is suitable to enable the medicament to be administered via a pressurized MDI. Additionally, the HFC propellant must be compatible with the components of the MDI device (such as containers, valves, and sealing gaskets, etc.) which is employed to administer the medicament. Preferred HFC propellants are 1,1,1,2-tetrafluoroethane (HFC-134(a)) and 1,1,1,2,3,3,3,-heptafluoropropane (HFC-227) . HFC-134(a) is particularly preferred. Other examples of HFC propellants are HFC-32 (difluoromethane) , HFC-143(a) (1,1,1- trifluoroethane) , HFC-134 (1,1,2,2-tetrafluoroethane) , and HFC-152a (1,1-difluoroethane) .
It will be apparent to those skilled in the art that non-halogenated hydrocarbon propellants may be used in place of the HFC propellants in the present invention. Examples of non-halogenated hydrocarbons are saturated hydrocarbons, including propane, n-butane, and isobutane, and ethers, including diethyl ether.
It will also be apparent to those skilled in the art that, although the use of a single HFC propellant is preferred, a mixture of two or more HFC propellants, or a mixture of at least one HFC propellant and one or more non- CFC propellants, may be employed in the aerosol solution formulation of the present invention.
A substantially non-aqueous HFC propellant/cosolvent system is preferred. Water may be present in small amounts as an impurity in the HFC propellant/cosolvent system, or, if desired, small amounts of water may be added (up to about 5% by weight) to the HFC/propellant system, for example, to aid in manufacturing. If desired, pharmaceutically acceptable excipients can be included in the aerosol solution formulations of the present invention. For example, a soluble surface active agent can be added in order to improve the performance of valve systems employed in the MDI devices used for the aerosol administration of the formulations. Examples of preferred surface active agents are oleic acid, sorbitan trioleate, lecithin, and isopropylmyristate. Other suitable lubricants are well known in the art (see, for example, Published European Patent Application No. 0372777 (EPO 893122705)). Other excipients are: (a) antioxidants, for example ascorbic acid and tocopherol; (b) taste masking agents, for example, menthol, sweeteners, and artificial or natural flavors; and (c) pressure modifying agents, for example, n-pentane, iso-pentane, neo-pentane, and n-hexane.
The medicaments used in the present invention may be any substance which is suitable for aerosol administration from an MDI or similar device. The medicament must be soluble in the HFC propellant/cosolvent system and, characteristically exhibit significant degradation or decomposition in the HFC propellant/cosolvent system. The degradation or decomposition of the medicament must be acid sensitive in that the rate of degradation or decomposition can be effectively reduced by the addition of acid.
The decomposition and the degradation of the medicament may occur by various chemical mechanisms, the most significant being interaction of the medicament with the cosolvent or with the water present in the system to form hydrolysis, esterification, and/or ether products.
The amount of medicament employed in the aerosol solution formulations of the present invention is that which is effective in producing the intended therapeutic effect, i.e., an amount such that one or more etered volumes of the formulation will deliver an effective amount of the medicament. It will be apparent to those skilled in the art that the potency of the particular medicament employed in the aerosol solution formulation will determine the amount of medicament in the formulation. In general, the medicament is present in an amount from about 0.001 to 10 percent by weight of the total weight of the formulation. An amount of from about 0.01 to 1.0 percent by weight of the total weight of the formulation is preferred.
Bronchodilators (in particular anticholinergics and sympathomimetics) are the preferred class of medicaments for use in the aerosol solution formulations of the present invention. Those skilled in the art will recognize that other classes of medicaments can in general be used. Examples of such classes are: antihistamines, antiallergics, antiinflammatories, PAF-antagonists, antitussives, antibiotics, mast cell stabilizers, mucolytics, antineoplastics, antiinfectives, vaccines, anesthetics, diagnostic agents, analgesics, antianginals, leukotriene antagonists, and 5-lipoxygenase antagonists. The medicaments can also be various types of organic molecules, including, but not limited to, hormones, enzymes, proteins, peptides, steroids, alkaloids, or combinations thereof.
The most preferred example of the medicaments for use in the aerosol solution formulations of the present invention is ipratropium bromide. Other preferred examples are oxitropium bromide (BA253) , albuterol, metapraterenol, tiotropium bromide (BA-679) , and fenoterol.
Other examples of medicaments are: Sympathomimetic Bronchodilators:
(a) alpha-adrenergic agonists: ephedrine, epinephrine. norfenefrine, phenylephrine, and phenylpropanolamine. (b) beta-adrenergic agonists: bambuterol, bitoterol, carbuterol, clenbuterol, ephedrine, formoterol, hexoprenaline, isoproterenol, mabuterol, pirbuterol, reproterol, rimiterol, terbutaline, and tulobuterol. Anticholinerαic Bronchodilators: telenzepine, troventol, and flubron. Alkaloids: atropine, scopolamine, and bromocriptine.
The medicaments used in the present invention may be in the form of either the free base or a pharmaceutically acceptable, non-toxic, salt thereof. Suitable salts are well known in the pharmaceutical and medicinal arts. The selection of a particular salt will depend upon the chemical nature of the base and the chemical stability and solubility of the salt in the formulation. Examples of salts that may be employed are: acetate, benezenesulphonate, benzoate, bicarbonate, bitartrate, bromide, calcium edentate, camsylate, esylate, fumarate, fluceptate, gluconate, glutamate, glycolarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methysulfate, mucate, napsylate, nitrate, pamoate (embonate) , pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulphate, tannate, tartrate, and triethiodide. Cationic salts may also be used. Examples of cationic salts include the alkali metals, e.g. sodium and potassium, and ammonium salts and salts of amines known to be pharmaceutically acceptable, e.g., glycine, ethylene diamine, choline, diethanolamine, triethanolamine, octadecylamine, diethylamine, triethylamine, l-amino-2-propanol-amino-2-(hydroxymethyl) propane-1,3-diol and 1-3(3, 4-dihydroxyphenyl)-2- isopropylaminoethanol.
The chemical nature of the medicament defines the nature of the cosolvent, which may be any one of a number of organic solvents that are toxicologically safe and amenable to MDI solution formulations. By "cosolvent" is meant any solvent which is miscible in the formulation in the amount desired and which, when added provides a formulation in which the medicament can be dissolved in therapeutically effective amounts. Examples of cosolvents that contain hydroxyl functions (or other functions) capable of interacting with the medicament(s) in the formulation are: alcohols, for example, ethyl alcohol and isopropyl alcohol; glycols, for example, propylene glycol, polyethylene glycols, polypropylene glycols, glycol ethers, and block copolymers of oxyethylene and oxypropylene; and other substances, for example, glycerol, polyoxyethylene alcohols, and polyoxtethylene fatty acid esters.
Examples of cosolvents that may be inert to interaction with the medicament(s) are hydrocarbons, for example, n-propane, n-butane, isobutane, n-pentane, iso- pentane, neo-pentane, and n-bexane; and ethers, for example, diethyl ether.
A preferred cosolvent according to this invention is ethyl alcohol (ethanol) .
The purpose of the cosolvent is to increase the solubility of the medicament and the excipients in the formulation. Thus, the amount of cosolvent present in the formulation defines the maximum amount of medicament and excipients that can be dissolved at a particular temperature. The selection of the acid in the aerosol solution formulations of this invention depends on the medicament used and the acid concentration needed to effect an acceptable rate of degradation of the medicament. The acid may be any strong inorganic or mineral acid, for example, hydrochloric acid, sulfuric acid, nitric acid, or phosphoric acid, or the like. The acid may also be selected from the group of acids known to those skilled in the art as organic acids, which are considered to be weak acids relative to the strong inorganic acids. Representative of this group and preferred in this invention are ascorbic acid and citric , , , acid, although other organic acids may also be suitable.
According to this invention an aerosol solution formulation comprising a particular medicament may be formulated using acids selected from either of the above groups. The methods used to introduce the acid into the formulation may include: (1) the direct addition of a strong inorganic acid or weak organic acid; (2) the addition of the medicament as an acidic salt thereby generating the correct acidity level in situ, and (3) combinations of (1) and (2) . Appropriate salts for introducing the medicament into the formulation will be apparent to those skilled in the art.
Laboratory experiments have demonstrated that aerosol solution formulations of ipratropium bromide in HFC- 134(a) and about 35% ethanol exhibit significant decomposition of the ipratropium bromide when stored at
50°C. The decomposition can be attributed to oxidation, chemical dehydration, hydrolysis and esterification.
However, tropic acid ethyl ester is the chief degradation product. This ester can be formed by the direct reaction of ethanol with ipratropium bromide or by hydrolysis of ipratropium bromide followed by esterification of tropic acid with ethanol. Addition of 1% water reduced the decomposition due to dehydration. Carrying out the reaction under nitrogen atmosphere reduced the oxidation products.
In aqueous solution the rate of hydrolysis and esterification is typically pH dependent. In aqueous solution, the degradation of ipratropium bromide exhibits a pH-rate minimum at pH 3.5. This corresponds to a hydrogen ion concentration of 3.2 x 10^ molar (M) . Although the concept of pH is poorly defined in non-aqueous systems, formulation evaluation studies were conducted using this concentration of hydrochloric acid in the HFC-134(a)/ethanol system containing ipratropium bromide. Samples stored at 50°C for five and one-half months exhibited less than 5.5% o loss of ipratropium bromide. A summary of these results is illustrated in Figure 1.
A range of chemical compositions is given in Table 1 for aerosol solution formulations containing ipratropium bromide, HFC-134(a), and a strong inorganic acid, such as - hydrochloric, nitric phosphoric, or sulfuric acid. The amount of alcohol present in the formulation defines the maximum amount of ipratropium bromide that can be dissolved at a particular temperature. The range of ipratropium bromide concentrations given in Table 1 is based on the 0 maximum, amount that can be safely dissolved without precipitation at room temperature for a given alcohol concentration. Acid content is given in units of normality which defines a pH range equivalent to 2.0 - 4.7 in an aqueous system.
TUTE SHEET (RULE 26) S'! TABLE 1 Ipratropium Bromide Aerosol Solution Formulations:
Range Of Chemical Compositions For A Strong Acid
Formulation
Component Contentper MDI Container
Ipratropium Bromide as the Monohydrate 0.001 - 2.5% wght./wght.
Dehydrated (Absolute) Ethanol, USP 1.0 - 50.0% wght./wght.
1,1,1,2-Tetrafluoroethane, (HFC-134(a)) 50.0 - 99.0% wght./wght. (DupontPharmaceutical Toxicity Grade)
Strong Inorganic Acid, USP/NF 0.01 - 0.00002 Normal (Hydrochloric Acid)
Water (Purified), USP 0.0 - 5.0% wght./wght.
A range of chemical compositions is given in Table
2 for aerosol solution formulations containing ipratropium bromide, HFC-134(a), and the weak organic acid, ascorbic acid. The range of ascorbic acid concentration presented in Table 2 was based on its acid dissociation constant (s), pKa(s), and the optimal pH range for a stable ipratropium bromide formulation (2.0-4.7) in an aqueous system. For ascorbic acid, 0.0045-275 mg/ml would be required in the formulation to correspond to an aqueous pH range of 2.0-4.7. However, solubility limitations must also be taken into consideration given the fact that ascorbic acid is only soluble to about 20 mg/ml in absolute ethanol and is expected to have a lesser solubility in an absolute ethanol/HFC-134a system. Optimally, about 0.30 mg/ml of ascorbic acid is expected to be required in such a formulation corresponding to a pH-degradation rate minimum of pH 3.5 for ipratropium bromide in an aqueous system. The information contained in Table 2 is presented for ascorbic acid and gives a range of ethanol content that is based on the expected room temperature solubility of ipratropium bromide (as the monohydrate) , not taking into account the solubility limit of ascorbic acid in such a HFC-134a system. Optimally, about 0.30 mg/ml of ascorbic acid is expected to be required in such a formulation corresponding to a pH- degradation rate minimum of pH 3.5 for ipratropium bromide in an aqueous system.
The range of concentration presented in Table 2 for ascorbic acid will differ for another weak organic acid depending on its acid dissociation constant(s) . For example about 0.0039-27.7 mg/ml of citric acid would be required in the formulation corresponding to an optimal aqueous pH range of 2.0-4.7 for ipratropium bromide, not taking into account solubility limitations for citric acid in an ethyl alcohol/HFC-134a system.
The range of acid concentration required to effect an acceptable rate of decomposition for medicaments in primarily non-aqueous solution aerosol formulations will depend primarily on the chemical composition of the formulation (such as choice of cosolvent(s) and the chemical nature of the medicaments(s) present. This range is expected to be about 0.10 - 0.0000001 normal for strong inorganic acids corresponding to an aqueous pH range of about 1.0-7.0 and must be calculated for weak organic acids depending on their pKa values.
TABLE 2 Ipratropium Bromide Aerosol Solution MDI Formulations:
Range Of Chemical Composition For A Weak Acid Formulation Component Contents per Container
Ipratropium Bromide as the Monohydrate 0.001 - 2.5 % wght. wght.
Dehydrated (Absolute) Ethanol, USP 1.0 - 50.0% wght./wght.
1,1,1,2-Tetrafluoroethane, HFC-134(a)) 50.0 - 99.0% wght./wght.
(Dupont Pharmaceutical Toxicity Grade) Ascorbic Acid, USP 0.00015 - 275 mg/ml
Water (Purified), USP 0.0 - 5.0% wght./wght.
The amount of drug that can be delivered through the valve of an aerosol solution formulation will depend on the active ingredient concentration (mg/ml ) in the formulation and the metering volume (ul ) of the valve . Commonly used valve sizes are 25 , 50 , 63 and 100 ul .
Metered dose inhalers containing aerosol solution formulations of medicaments can be manufactured using a number of conventional processing methods . One method, which is useful in the laboratory for the manufacture of small laboratory scale lots , is Dual Stage Pressure Fill . This method is shown in Tables 3 and 4 for two specific ipratropium bromide solution formulations using a 50 -ul valve . Two methods for large scale manufacture are Single- stage Cold Fill and Single- Stage Pressure Fill .
C 26 TABLE 3
Ipratropium Bromide Inhalation Aerosol, 0.021 g Drug
Delivered Through The Valve, 12 ml
I. Composition
Component Contents per Container
Ipratropium Bromide Monohydrate 0.00505
Dehydrated (Absolute) Alcohol, USP 2.02500
1,1, 1 ,2-Tetrafluoroethane, HFC-134a) 11.40209
(Dupont Pharmaceutical Toxicity Grade)
Nitric Acid, USP/NF 0.00036
Water (Purified), USP 0.06750
TOTAL: 13.50000
I . Device Components
Suitable Aerosol Container 50 ul Aerosol Metering Valve
III . Brief Description of Processing Method
An active ingredient concentrate is prepared by dissolving the ipratropium bromide , as the monohydrate , nitric acid, and water in ethyl alcohol . The concentrate is added to an appropriate filling apparatus . The active ingredient concentrate is dispensed into aerosol containers . The headspace of the containers is purged with nitrogen or HFC- 134a vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valves . The HFC- 134a propellant is then pressure- filled into the sealed containers . TABLE 4 Ipratropium Bromide Inhalation Aerosol, 0.021 mg Drug Delivered Through The Valve. 12 ml
I. Composition
Stated Contents Component Per Container (g)
Ipratropium Bromide Monohydrate 0.00505
Dehydrated (Absolute) Ethyl Alcohol, USP 2.02500
1,1,1,2-Tetrafluoroethane (HFC-134A), 11.26745
(Dupont Pharmaceutical Toxicity Grade)
Ascorbic Acid, USP 0.13500
Water (Purified), USP 0.06750
TOTALl 3.50000
II . Device Components : Suitable Aerosol Container
50 ul Aerosol Metering Valve
III. Brief Description Of Processing Method
An active ingredient concentrate is prepared by dissolving the ipratropium bromide, as the monohydrate, ascorbic acid and water in ethyl alcohol. The concentrate is added to an appropriate filling apparatus. The active ingredient concentrate is dispensed into aerosol containers, the headspace of the containers is purged with Nitrogen or HFC-134a vapor (purging ingredients should not contain more than 1 ppm oxygen) and is sealed with valves. The HFC-134a propellant is then pressure filed into the sealed containers.

Claims

We Claim:
1. An aerosol solution formulation comprising a medicament, an HFC propellant, an organic cosolvent, and either a strong inorganic acid or weak organic acid.
2. An aerosol solution formulation according to Claim 1 wherein the HFC propellant is 1,1,1,2- tetrafluoroethane.
3. An aerosol solution formulation according to Claim 2 wherein the organic cosolvent is ethyl alcohol.
4. An aerosol solution formulation according to
10 Claim 3 wherein the ethyl alcohol is in the range of about 1.0 to 50.0% wght./wght. of the formulation.
5. An aerosol solution formulation according to Claim 3 wherein the strong inorganic acid is selected from the group consisting of sulfuric acid, hydrochloric acid,
15 nitric acid, and phosphoric acid.
6. An aerosol solution formulation according to Claim 5 wherein the strong inorganic acid is in the range of about 0.000001 to 0.1 Normal.
7. An aerosol solution formulation according to
20 Claim 3 wherein the weak organic acid is selected from the group consisting of ascorbic acid and citric acid.
8. An aerosol solution formulation according to Claim 3 which contains water in an amount up to about 5.0% wght./wght.
--
9. An aerosol solution formulation according to
Claim 1 wherein the HFC propellant is 1,1,1,2,3,3,3,- heptafluoropropane.
10. An aerosol solution formulation according to Claim 9 wherein the organic cosolvent is ethyl alcohol.
30 11. An aerosol solution formulation according to Claim 10 wherein the ethyl alcohol is in the range of about 1.0 to 50.0% wght./wght. of the formulation.
12. An aerosol solution formulation according to Claim 10 wherein the strong inorganic acid is selected from 5 the group consisting of sulfuric acid, hydrochloric acid nitric acid, and phosphoric acid.
13. An aerosol solution formulation according to Claim 12 wherein the strong inorganic acid is in the range of about 0.0000001 to 0.1 Normal.
14. An aerosol solution formulation according to Claim 10 wherein the weak organic acid is selected from the group consisting of ascorbic acid and citric acid.
15. An aerosol solution formulation according to Claim 14 wherein the weak organic acid is in the range of about 0.00015 to 275 mg/ml.
16. An aerosol solution formulation according to Claim 10 which contains water in an amount up to about 0.0 to 5.0% wght./wght.
17. An aerosol solution formulation comprising ipratropium bromide, an HFC propellant, ethyl alcohol and either a strong inorganic acid or weak organic acid.
18. An aerosol solution formulation according to Claim 17 wherein the HFC propellant is 1,1,1,2- tetrafluoroethane.
19. An aerosol solution formulation according to Claim 18 wherein the ethyl alcohol is within the range of about 1.0 to 50.0% wght./wght.
20. An aerosol solution formulation according to Claim 18 wherein the strong inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.
21. An aerosol solution formulation according to Claim 20 wherein the strong inorganic acid is within the range of about 0.00002 to 0.01 Normal.
22. An aerosol solution formulation according to Claim 18 wherein the weak organic acid is selected from the group consisting of ascorbic acid and citric acid.
23. An aerosol solution formulation according to Claim 22 wherein the weak organic acid is ascorbic acid and which is within the range of about 0.0045 to 275 mg/ml.
24. An aerosol solution formulation according to Claim 22 wherein the weak organic acid is citric acid and which is within the range of about 0.0039 to 27.7 mg/ml.
25. An aerosol solution formulation according to Claim 17 wherein the HFC propellant is 1,1,1,2,3,3,3- heptafluoropropane.
26. An aerosol solution formulation according to Claim 25 wherein the ethyl alcohol is within the range of about 1.0 to 50.0% wght./wght.
27. An aerosol solution formulation according to Claim 25 wherein the strong inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.
28. An aerosol solution formulation according to Claim 26 wherein the strong inorganic acid is within the range of about 0.00002 to 0.01 Normal.
29. An aerosol solution formulation according to Claim 25 wherein the weak organic acid is selected from the group consisting of ascorbic acid and citric acid.
30. An aerosol solution formulation according to
Claim 29 wherein the weak organic acid is ascorbic acid and which is within the range of about 0.0045 to 275 mg/ml.
31. An aerosol solution formulation according to Claim 29 wherein the weak organic acid is citric acid and which is within the range of about 0.0039 to 27.7 mg/ml.
32. An aerosol solution formulation according to Claim 1 wherein the medicament is selected the group consisting of ipratropium bromide, oxitropium bromide, albuterol, metaproterenol, tiotropiumbromide and fenoterol.
33. An aerosol solution formulation according to
Claim 32 wherein the HFC propellant is 1,1,1,2- tetrafluoroethane.
34. An aerosol solution formulation according to Claim 33 wherein the cosolvent is ethyl alcohol.
35. An aerosol solution formulation according to Claim 32 wherein the HFC propellant is 1,1,1,2,3,3,3- heptafluoropropane.
36. An aerosol solution formulation according to Claim 35 wherein the cosolvent is ethyl alcohol.
37. An aerosol solution formulation comprising a medicament, an HFC propellant, a cosolvent, and either a strong inorganic acid or weak organic acid, wherein the medicament; is soluble in the propellant/cosolvent system, tends to degrade or decompose based on the interaction between the medicament and the cosolvent or water, and degrades or decomposes by an acid sensitive mechanism such that the rate of degradation or decomposition can be effectively reduced by the addition of acid.
38. An aerosol formulation according to Claim 37 wherein the HFC propellant is 1,1,1,2-tetrafluoroethane and the cosolvent is ethyl alcohol.
39. An aerosol formulation according to Claim 37 wherein the HFC propellant is 1,1,1,2,3,3,3- heptafluoropropane and the cosolvent is ethyl alcohol.
40. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises a medicament, 1,1,1,2-tetrafluoroethane and a cosolvent, and wherein the medicament degrades by interaction with the cosolvent or water or other mechanism, such degradation having the capability of being reduced to acceptable levels by the addition of acid, such method comprising the addition of an amount of a strong inorganic acid or weak organic acid to the aerosol solution formulation.
41. A method for stabilizing an aerosol solution formulation wherein the aerosol solution formulation comprises amedicament, 1,1,1,2,3,3,3-heptafluoropropane and a cosolvent, and wherein the medicament degrades by interaction with the cosolvent or water or other mechanism, such degradation having the capability of being reduced to acceptable levels by the addition of acid, such method comprising the addition of an amount of a strong inorganic acid or weak organic acid to the aerosol solution formulation.
42. In a method of treating a patient by the administration of an aerosol solution formulation the improvement wherein comprises administering said aerosol solution formulation as a stabilized aerosol solution comprising a medicament, 1,1,1,2-tetrafluoroethane, a cosolvent, and either a strong inorganic acid or a weak organic acid.
43. A method of treatment according to Claim 42 wherein said medicament in the stabilized aerosol solution formulation is ipratropium bromide and the cosolvent is ethyl alcohol.
44. In a method of treating a patient by the administration of an aerosol solution formulation the improvement wherein comprises administering said aerosol solution formulation as a stabilized aerosol solution comprising a medicament, 1,1,1,2,3,3,3-heptafluoropropane, a cosolvent, and either a strong inorganic acid or a weak organic acid.
45. A method of treatment according to Claim 44 wherein said medicament in the stabilized aerosol solution formulation is ipratropium bromide and the cosolvent is ethyl alcohol.
PCT/US1993/011856 1992-12-09 1993-12-06 Stabilized medicinal aerosol solution formulations WO1994013263A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60486/94A AU6048694A (en) 1992-12-09 1993-12-06 Stabilized medicinal aerosol solution formulations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98785292A 1992-12-09 1992-12-09
US07/987,852 1992-12-09
US15354993A 1993-11-22 1993-11-22
US08/153,549 1993-11-22

Publications (1)

Publication Number Publication Date
WO1994013263A1 true WO1994013263A1 (en) 1994-06-23

Family

ID=26850651

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1993/011856 WO1994013263A1 (en) 1992-12-09 1993-12-06 Stabilized medicinal aerosol solution formulations
PCT/US1993/011801 WO1994013262A1 (en) 1992-12-09 1993-12-06 Stabilized medicinal aerosol solution formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011801 WO1994013262A1 (en) 1992-12-09 1993-12-06 Stabilized medicinal aerosol solution formulations

Country Status (28)

Country Link
US (3) US5676930A (en)
EP (1) EP0673240B1 (en)
JP (1) JP3009924B2 (en)
KR (1) KR100312357B1 (en)
AT (1) ATE177941T1 (en)
AU (2) AU6048694A (en)
BG (1) BG62382B1 (en)
BR (1) BR9307627A (en)
CA (1) CA2151383C (en)
CZ (1) CZ284203B6 (en)
DE (1) DE69324161T2 (en)
DK (1) DK0673240T3 (en)
ES (1) ES2129117T3 (en)
FI (1) FI114283B (en)
GB (1) GB2288978B (en)
GR (1) GR3030529T3 (en)
HK (1) HK1011620A1 (en)
HU (1) HU221163B1 (en)
LV (1) LV10911B (en)
NO (1) NO311487B1 (en)
NZ (1) NZ259192A (en)
PL (1) PL177078B1 (en)
RO (1) RO117414B1 (en)
RU (1) RU2126248C1 (en)
SG (1) SG52459A1 (en)
SK (1) SK280911B6 (en)
UA (1) UA27143C2 (en)
WO (2) WO1994013263A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022081A1 (en) * 1995-01-17 1996-07-25 Omega Pharmaceutical, Incorporated Liquid stable vitamin c compositions and delivery systems, and methods of making and uses thereof
WO1997001329A1 (en) * 1995-06-27 1997-01-16 Boehringer Ingelheim Kg New, stable medicinal compositions for generating propellant-free aerosols
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
EP1291013A3 (en) * 1998-10-17 2003-11-26 Boehringer Ingelheim Pharma GmbH & Co.KG Storage-stable pharmaceutical compositions
EP1446045A2 (en) * 2001-10-26 2004-08-18 Dey L.P. An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
EP1466594A2 (en) * 2000-05-22 2004-10-13 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
WO2005084640A1 (en) * 2004-02-27 2005-09-15 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7186402B2 (en) 2001-12-21 2007-03-06 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US7718162B2 (en) 2001-12-21 2010-05-18 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
US8084461B2 (en) 2001-10-26 2011-12-27 Dey, L.P. Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2129117T3 (en) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma DISSOLUTION FORMULATIONS IN THE FORM OF STABILIZED MEDICINAL SPRAY.
CA2217950C (en) * 1995-04-14 2001-12-25 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
DE19528145A1 (en) * 1995-08-01 1997-02-06 Boehringer Ingelheim Kg New drugs and their use
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US20030215396A1 (en) 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for the production of propellant-free aerosols
US6471943B1 (en) 1996-12-30 2002-10-29 Battelle Pulmonary Therapeutics, Inc. Formulation and method for treating neoplasms by inhalation
CZ296966B6 (en) * 1997-02-24 2006-08-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical composition
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
SK284756B6 (en) * 1998-06-18 2005-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical preparation for propellant driven metered dose inhalers, where the propellant is fluorohydrocarbon, containing a combination of two or more active substances
DZ2947A1 (en) * 1998-11-25 2004-03-15 Chiesi Farma Spa Pressure metered dose inhaler.
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
DE19921693A1 (en) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Pharmaceutical composition for treating respiratory disorders, e.g. asthma, comprises combination of anticholinergic and beta-mimetic agents having synergistic bronchospasmolytic activity and reduced side-effects
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US20040002548A1 (en) * 1999-05-12 2004-01-01 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
IT1313553B1 (en) 1999-07-23 2002-09-09 Chiesi Farma Spa OPTIMIZED FORMULATIONS CONSTITUTED BY SOLUTIONS OF STEROIDS GIVEN BY INHALATION.
GB2354007B (en) 1999-09-11 2003-10-22 Glaxo Group Ltd Pharmaceutical formulation of fluticasone propionate
JP2003518484A (en) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド Pharmaceutical aerosol formulations of salmeterol and fluticasone propionate
IT1317720B1 (en) * 2000-01-07 2003-07-15 Chiesi Farma Spa DEVICE FOR THE ADMINISTRATION OF AEROSOL DOSED PRESSURIZED INPROPELLENT HYDROFLUOROALKANS.
IT1317846B1 (en) * 2000-02-22 2003-07-15 Chiesi Farma Spa FORMULATIONS CONTAINING AN ANTICOLINERGIC DRUG FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE BRONCOPNEUMOPATHY.
IT1318514B1 (en) * 2000-05-12 2003-08-27 Chiesi Farma Spa FORMULATIONS CONTAINING A GLUCOCORTICOSTEROID DRUG FOR THE TREATMENT OF BRONCOPOLMONARY DISEASES.
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
ATE276253T1 (en) * 2000-10-12 2004-10-15 Boehringer Ingelheim Pharma CRYSTALLINE MONOHYDRATE OF TIOTROPIUM BROMIDE, METHOD FOR PRODUCING THEREOF AND USE THEREOF FOR PRODUCING A MEDICINAL PRODUCT
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10063957A1 (en) * 2000-12-20 2002-06-27 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and dopamine agonists
US6620438B2 (en) * 2001-03-08 2003-09-16 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists
US20020085978A1 (en) * 2000-11-10 2002-07-04 Mina Buenafe Degradation-resistant glucocorticosteroid formulations
US20100310477A1 (en) * 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
US6455028B1 (en) 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
ES2222294T3 (en) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. OPTIMIZED FORMULATION OF TOBRAMYCIN FOR ADMINISTRATION IN THE FORM OF AEROSOL.
DE10135355C1 (en) * 2001-07-20 2003-04-17 Schering Ag Conjugates of macrocyclic metal complexes with biomolecules and their use in the preparation of NMR and radiodiagnostic agents and radiotherapy
SI1446119T1 (en) 2001-09-18 2006-08-31 Nycomed Danmark Aps Compositions comprising ipatropium and xylometazoline for treatment of the common cold
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
MXPA04003928A (en) * 2001-10-26 2005-03-31 Dey L P Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma.
JP2003221335A (en) 2001-10-26 2003-08-05 Dey Lp Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptom of chronic obstructive pulmonary disease
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
DE10161368A1 (en) * 2001-12-14 2003-07-10 Messer Griesheim Gmbh Cryogenic cooling of aerosol product mixtures, especially for filling pharmaceutical dosed aerosols, comprises controlled thermal contact with vaporized cooling gas in heat exchanger
EP1458354A1 (en) * 2001-12-21 2004-09-22 3M Innovative Properties Company Medicinal aerosol formulations comprising ion pair complexes
WO2003074024A1 (en) * 2002-03-01 2003-09-12 Chiesi Farmaceutici S.P.A Formoterol superfine formulation
US20040126325A1 (en) * 2002-03-12 2004-07-01 David Lewis Medicinal aerosol solution formulation products with improved chemical stability
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
US7311894B2 (en) * 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
AU2003233583A1 (en) * 2002-05-24 2003-12-12 Agennix Incorporated Oral lactoferrin in the treatment of respiratory disorders
AU2003276837B2 (en) * 2002-06-12 2006-07-20 Epigenesis Pharmaceuticals, Llc. Combination of anti-muscarinic agents and non-glucocorticoid steroids
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US20050058606A1 (en) * 2002-12-16 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing HFC solution formulations
MXPA05006383A (en) * 2002-12-16 2005-08-29 Boehringer Ingelheim Pharma Tiotropium containing hfc solution formulations.
EP1915985A1 (en) * 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants
PT1608336E (en) * 2003-03-20 2008-04-21 Boehringer Ingelheim Pharma Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US7273603B2 (en) * 2003-07-11 2007-09-25 Boehringer Ingelheim International Gmbh HFC solution formulations containing an anticholinergic
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
AR041873A1 (en) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
US20050255050A1 (en) * 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Powder formulations for inhalation, comprising enantiomerically pure beta agonists
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
EA013428B1 (en) * 2004-07-02 2010-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
EA013405B1 (en) 2005-02-25 2010-04-30 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Pharmaceutical aerosol composition for pressurized metered dose inhalers
WO2006114379A1 (en) * 2005-04-23 2006-11-02 Boehringer Ingelheim International Gmbh Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent
RU2417224C2 (en) 2005-05-02 2011-04-27 Бёрингер Ингельхайм Интернациональ Гмбх New crystalline forms of tiotropium bromide
EP1917253B1 (en) * 2005-08-15 2015-01-07 Boehringer Ingelheim International Gmbh Method for producing betamimetics
RU2457832C2 (en) * 2005-09-25 2012-08-10 Сипла Лимитед Troventol-based composition
US20070088030A1 (en) * 2005-10-10 2007-04-19 Barbara Niklaus-Humke Aerosol formulations for the inhalation of beta-agonists
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
DE102006017320A1 (en) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol suspension formulations with TG 227 ea or TG 134 a as propellant
DE102006023770A1 (en) * 2006-05-20 2007-11-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Propellant-free aerosol formulation for inhalation
WO2008008494A2 (en) * 2006-07-13 2008-01-17 Accentia Biopharmaceuticals, Inc. Methods and compositions for treating mucosal inflammation
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2201934A1 (en) 2008-12-23 2010-06-30 CHIESI FARMACEUTICI S.p.A. Tiotropium aerosol formulation products with improved chemical stability
WO2010112358A2 (en) 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh Method for coating a surface of a component
EP3508239B1 (en) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalant apparatus and atomizer
ES2533535T3 (en) 2009-11-17 2015-04-10 Cipla Limited Solutions for inhalation
EP2504051B1 (en) 2009-11-25 2019-09-04 Boehringer Ingelheim International GmbH Nebulizer
EP2504052B1 (en) 2009-11-25 2022-07-27 Boehringer Ingelheim International GmbH Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
EP2512438B1 (en) 2009-12-16 2017-01-25 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
CA2785321C (en) 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
JP5874724B2 (en) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
JP5409594B2 (en) * 2010-12-22 2014-02-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Stable pharmaceutical solution formulation for pressurized metered dose inhalers
US20120204871A1 (en) * 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
GB201200525D0 (en) 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
GB201200504D0 (en) 2011-12-19 2012-02-22 Teva Branded Pharmaceutical Prod R & D Inc An inhaler
WO2013127738A1 (en) 2012-02-28 2013-09-06 Boehringer Ingelheim International Gmbh Novel propellant-gas-containing tiotropium formulation
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
RU2496477C1 (en) * 2012-09-20 2013-10-27 Шолекс Девелопмент Гмбх Ipratropium bromide solution
JP6643231B2 (en) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Nebulizer
ES2836977T3 (en) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizer
RU2536253C1 (en) * 2013-10-09 2014-12-20 Шолекс Девелопмент Гмбх Combined aerosol preparation for treating respiratory diseases
PL2897589T3 (en) 2013-11-22 2018-06-29 Teva Branded Pharmaceutical Products R & D, Inc. An inhalable medicament
AU2014352813A1 (en) * 2013-11-22 2016-05-26 Teva Branded Pharmaceutical Products R&D, Inc. An inhalable medicament
WO2015169732A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Container, nebulizer and use
DK3139984T3 (en) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Atomizer
HRP20220596T1 (en) 2014-05-07 2022-06-24 Boehringer Ingelheim International Gmbh Nebulizer
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
RU2577289C1 (en) * 2015-03-26 2016-03-10 Шолекс Девелопмент Гмбх Aerosol preparation based on fenoterol hydrobromide for treating respiratory diseases
EP3922240B1 (en) * 2016-09-19 2023-06-21 Mexichem Fluor S.A. de C.V. Pharmaceutical composition comprising tiotropium bromide
EP3569221A1 (en) * 2018-05-17 2019-11-20 Notoxins IP B.V. Aqueous formulations comprising ipratropium for topical treatment of hyperhidrosis
WO2020152548A1 (en) * 2019-01-24 2020-07-30 Glenmark Pharmaceuticals Limited Stable aerosol inhalation compositions of formoterol
CN111297835B (en) * 2019-12-20 2022-11-25 上海方予健康医药科技有限公司 Inhalation aerosol containing anticholinergic medicine and its preparation process and usage
IL301617A (en) * 2020-10-09 2023-05-01 Chiesi Farm Spa A pharmaceutical formulation for pressurised metered dose inhaler

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
EP0372777A2 (en) * 1988-12-06 1990-06-13 Riker Laboratories, Inc. Medicinal aerosol formulations
WO1990007333A1 (en) * 1989-01-06 1990-07-12 Riker Laboratories, Inc. Fentanyl containing aerosol compositions
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
WO1991011496A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gases and their use in medical preparations
EP0504112A2 (en) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmaceutical aerosol formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1178889A (en) * 1980-08-28 1984-12-04 Kenneth S. Su Intranasal formulation
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
ES2084360T3 (en) * 1991-06-10 1996-05-01 Schering Corp FORMULATIONS OF CHLOROFLUOROCARBON-FREE AEROSOLS.
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
ES2129117T3 (en) * 1992-12-09 1999-06-01 Boehringer Ingelheim Pharma DISSOLUTION FORMULATIONS IN THE FORM OF STABILIZED MEDICINAL SPRAY.
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868691A (en) * 1956-03-21 1959-01-13 Riker Laboratories Inc Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
EP0372777A2 (en) * 1988-12-06 1990-06-13 Riker Laboratories, Inc. Medicinal aerosol formulations
WO1990007333A1 (en) * 1989-01-06 1990-07-12 Riker Laboratories, Inc. Fentanyl containing aerosol compositions
WO1991011495A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gas mixtures and their use in medical preparations
WO1991011496A1 (en) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Novel vehicle gases and their use in medical preparations
EP0504112A2 (en) * 1991-03-14 1992-09-16 Ciba-Geigy Ag Pharmaceutical aerosol formulations

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022081A1 (en) * 1995-01-17 1996-07-25 Omega Pharmaceutical, Incorporated Liquid stable vitamin c compositions and delivery systems, and methods of making and uses thereof
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
WO1997001329A1 (en) * 1995-06-27 1997-01-16 Boehringer Ingelheim Kg New, stable medicinal compositions for generating propellant-free aerosols
US7566445B1 (en) 1996-08-01 2009-07-28 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US9650203B2 (en) 1996-08-01 2017-05-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
US8834849B2 (en) 1996-08-01 2014-09-16 Norton Healthcare Limited Medicinal aerosols and methods of delivery thereof
EP1291013A3 (en) * 1998-10-17 2003-11-26 Boehringer Ingelheim Pharma GmbH & Co.KG Storage-stable pharmaceutical compositions
EP1466594A2 (en) * 2000-05-22 2004-10-13 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP1466594A3 (en) * 2000-05-22 2004-12-01 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP2223682A1 (en) * 2000-05-22 2010-09-01 Chiesi Farmaceutici S.p.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US8084461B2 (en) 2001-10-26 2011-12-27 Dey, L.P. Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
EP1446045A4 (en) * 2001-10-26 2010-07-21 Dey L P An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
EP1446045A2 (en) * 2001-10-26 2004-08-18 Dey L.P. An albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US7718162B2 (en) 2001-12-21 2010-05-18 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
US7186402B2 (en) 2001-12-21 2007-03-06 3M Innovative Properties Company Medicinal aerosol compositions with an amide and/or ester containing excipient compound
EA010311B1 (en) * 2004-02-27 2008-08-29 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Aerosol solution formulations, pressurized metered dose inhalers and method for filling thereof
WO2005084640A1 (en) * 2004-02-27 2005-09-15 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
GB2584686A (en) * 2019-06-11 2020-12-16 Mexichem Fluor Sa De Cv Methods
WO2020249934A1 (en) * 2019-06-11 2020-12-17 Mexichem Fluor S.A. De C.V. Method for charging a container for use with a medication delivery apparatus, container for such an apparatus and method for treating a patient

Also Published As

Publication number Publication date
GB9511669D0 (en) 1995-08-23
US6045778A (en) 2000-04-04
PL309333A1 (en) 1995-10-02
BR9307627A (en) 1999-06-15
ATE177941T1 (en) 1999-04-15
EP0673240B1 (en) 1999-03-24
DK0673240T3 (en) 1999-10-11
DE69324161T2 (en) 1999-10-28
BG99760A (en) 1996-02-28
ES2129117T3 (en) 1999-06-01
JP3009924B2 (en) 2000-02-14
SG52459A1 (en) 1998-09-28
LV10911A (en) 1995-12-20
SK76095A3 (en) 1997-01-08
LV10911B (en) 1996-04-20
NO311487B1 (en) 2001-12-03
GB2288978B (en) 1997-04-09
HUT72985A (en) 1996-06-28
CZ284203B6 (en) 1998-09-16
NO952269D0 (en) 1995-06-08
WO1994013262A1 (en) 1994-06-23
KR100312357B1 (en) 2002-04-24
US5955058A (en) 1999-09-21
KR950703932A (en) 1995-11-17
UA27143C2 (en) 2000-02-28
BG62382B1 (en) 1999-10-29
FI952842A0 (en) 1995-06-09
GR3030529T3 (en) 1999-10-29
AU5740594A (en) 1994-07-04
CA2151383A1 (en) 1994-06-23
JPH08509459A (en) 1996-10-08
PL177078B1 (en) 1999-09-30
RU2126248C1 (en) 1999-02-20
DE69324161D1 (en) 1999-04-29
CA2151383C (en) 2005-02-08
HU9501663D0 (en) 1995-08-28
CZ149095A3 (en) 1995-12-13
NO952269L (en) 1995-06-08
GB2288978A (en) 1995-11-08
US5676930A (en) 1997-10-14
EP0673240A1 (en) 1995-09-27
HU221163B1 (en) 2002-08-28
AU6048694A (en) 1994-07-04
HK1011620A1 (en) 1999-07-16
NZ259192A (en) 1997-05-26
RO117414B1 (en) 2002-03-29
SK280911B6 (en) 2000-09-12
FI952842A (en) 1995-06-09
AU680227B2 (en) 1997-07-24
FI114283B (en) 2004-09-30

Similar Documents

Publication Publication Date Title
AU680227B2 (en) Stabilized medicinal aerosol solution formulations
EP1646364B1 (en) Hfc solution formulations containing an anticholinergic
JP3323199B2 (en) Aerosol formulation without chlorofluorocarbon
US5605674A (en) Medicinal aerosol formulations
EP0499344B1 (en) Medicinal aerosol formulations
US20090175802A1 (en) Tiotropium containing hfc solution formulations
KR20050085650A (en) Tiotropium containing hfc solution formulations
CN1054282C (en) Stabilized medicinal aerosol solution formulations
NZ243056A (en) Aerosol formulation containing a medicament, tetrafluoroethane and isopropyl myristate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WA Withdrawal of international application
122 Ep: pct application non-entry in european phase
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA